Pneumococcal Conjugate Vaccine Administration During Therapy for Pediatric Leukemia
Nigel W Crawford, Anne Balloch, Leena Tikkanen, Francoise Merchinaud, Peter Downie, Jim P Buttery
The Pediatric Infectious Disease Journal | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015
BACKGROUND: Pediatric leukemia patients are at high risk of invasive pneumococcal disease. The study aim was to determine the antibody response to a 10-valent pneumococcal conjugate vaccine (PCV10) administered during chemotherapy. METHODS: An open-label study in pediatric leukemia patients: Group 1 had completed a primary 7-valent (PCV7) course and received a single PCV10 dose. Group 2 were PCV immunization naïve and received 3 doses of PCV10, administered 2 months apart. Serum samples were taken at baseline and 1 month post each PCV10 dose. Antipneumococcal serotype-specific IgG to 10 serotypes were measured by enzyme-linked immunosorbent assay and the functional response to 4 serotypes (1..View full abstract
N.W.C. and J.P.B. have acted as chief investigators for epidemiological studies sponsored by vaccine manufacturers (CSL) and serological testing (Merck). All payments, including for sitting on advisory boards (N.W.C.), data safety monitoring boards (J.P.B.), lecturing (N.W.C.) and travel expenses for attendance at scientific meetings, are paid directly to an administrative fund held by Murdoch Childrens Research Institute. The other authors have no conflicts of interest to disclose.